Thiazolidinediones in dermatology

International Journal of Dermatology

Volumn 46, Issue 6, 2007, Pages 557-563

  Boyd, Alan S ^a  

^a VANDERBILT UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

15 DEOXY PROSTAGLANDIN J2; ANTIRETROVIRUS AGENT; CIGLITAZONE; CYTOKINE; GLITAZONE DERIVATIVE; GLUCOSE; INSULIN; METFORMIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PIOGLITAZONE; PLACEBO; PROSTAGLANDIN DERIVATIVE; PROTEINASE INHIBITOR; RETINOID X RECEPTOR; ROFECOXIB; ROSIGLITAZONE; STAVUDINE; TROFOSFAMIDE; TROGLITAZONE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ADIPOCYTE; ANEMIA; ANGIONEUROTIC EDEMA; ANGIOSARCOMA; CELL DIFFERENTIATION; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CYTOKINE PRODUCTION; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG INDICATION; DRUG MECHANISM; DRUG RECEPTOR BINDING; DYSLIPIDEMIA; GENETIC TRANSCRIPTION; GLUCOSE TRANSPORT; GLYCEMIC CONTROL; HIRSUTISM; HIV ASSOCIATED LIPODYSTROPHY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INSULIN SENSITIVITY; INTRAUTERINE GROWTH RETARDATION; LIPODYSTROPHY; LIVER TOXICITY; MELANOMA; NECROBIOSIS LIPOIDICA; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OVARY POLYCYSTIC DISEASE; PARADOXICAL DRUG REACTION; PERIPHERAL EDEMA; PLASMA VOLUME; PSORIASIS; PSORIATIC ARTHRITIS; REVIEW; SIDE EFFECT; SKIN DISEASE; UNSPECIFIED SIDE EFFECT; VASCULAR TUMOR; WEIGHT GAIN;

HIRSUTISM; HIV-ASSOCIATED LIPODYSTROPHY SYNDROME; HUMANS; MELANOMA; PPAR GAMMA; PSORIASIS; RETINOID X RECEPTORS; SKIN DISEASES; SKIN NEOPLASMS; THIAZOLIDINEDIONES; TRANSCRIPTION, GENETIC; VASCULAR NEOPLASMS;

EID: 34250316592     PISSN: 00119059     EISSN: 13654632     Source Type: Journal    
DOI: 10.1111/j.1365-4632.2007.03273.x     Document Type: Review

References (47)

1. Robertshaw H, Friedman PS. Pioglitazone: A promising therapy for psoriasis. Br J Dermatol 2005; 152: 189-191.
2. Pershadsingh HA, Sproul JA, Benjamin E, et al. Treatment of psoriasis with troglitazone therapy. Arch Dermatol 1998; 134: 1304-1305.
3. Mossner R, Schulz U, Kruger U, et al. Agonists of peroxisome proliferators-activated receptor γ inhibit cell growth in malignant melanoma. J Invest Dermatol 2002; 119: 576-582.
4. Issemann I, Green S. Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators. Nature 1990; 347: 645-650.
5. Gelman L, Fruchart JC, Auwerx J. An update on the mechanisms of action of the peroxisome proliferators-activated receptors (PPARs) and their roles in inflammation and cancer. Cell Mol Life Sci 1999; 55: 932-943.
6. Shafiq N, Malhotra S, Pahndhi P, et al. Pilot trial: Pioglitazone versus placebo in patients with plaque psoriasis (the P6). Int J Dermatol 2005; 44: 328-333.
7. Yki-Jarvinen H. Thiazolidinediones. N Engl J Med 2004; 351: 1106-1118.
8. Grinberg A, Park KW. Nuclear peroxisome proliferator-activated receptors and thiazolidinediones. Int Anethesiol Clin 2005; 43: 1-21.
9. Placha W, Gil D, Dembinska-Kiec A, et al. The effect of PPARγ ligands on the proliferation and apoptosis of human melanoma cells. Melanoma Res 2003; 13: 447-456.
10. Ellis CN, Varani J, Fischer GJ, et al. Troglitazone improves psoriasis and normalizes models of proliferative skin disease: Ligand for peroxisome proliferators-activated receptor-γ inhibit keratinocyte proliferation. Arch Dermatol 2000; 136: 609-616.
11. Konopleva M, Elstner E, McQueen TJ, et al. Peroxisome proliferators-activated receptor γ and retinoid X receptor ligands are potent inducers of differentiation and apoptosis in leukemias. Mol Cancer Ther 2004; 3: 1249-1262.
12. Dragnev KH, Rigas JR, Dmitrovsky E. The retinoids and cancer prevention mechanisms. Oncologist 2000; 5: 361-368.
13. Cheng SX, Kupper T. A new rexinoid for cutaneous T-cell lymphoma. Arch Dermatol 2001; 137: 649-652.
14. Lehmann JM, Lenhard JM, Oliver BB, et al. Peroxisome proliferators-activated receptors alpha and gamma are activated by indomethacin and other non-steroidal anti-inflammatory drugs. J Biol Chem 1997; 272: 3406-3410.
15. Pershadsingh HA, Benson SC, Ellis CN. Improvement in psoriasis with rosiglitazone in a diabetic and a nondiabetic patient. Skin Med 2005; 4: 386-390.
16. Minamikawa J, Tanaka S, Yamauchi M, et al. Potent inhibitory effect of troglitazone on carotid arterial wall thickness in type 2 diabetes. J Clin Endocrinol Metab 1998; 83: 1818-1820.
17. Shadid S, Jensen MD. Angioneurotic edema as a side effect of pioglitazone. Diabetes Care 2002; 25: 405.
18. Mao-Qiang M, Fowler AJ, Schmuth M, et al. Peroxisome-proliferator-activated receptor (PPAR)-γ activation stimulates keratinocyte differentiation. J Invest Dermatol 2004; 123: 305-312.
19. Kuenzli S, Saurat JH. Effect of topical PPARδ/δ and PPARγ agonists on plaque psoriasis. Dermatology 2003; 206: 252-256.
20. Itoh S, Kanazuka A, Akimoto T. Combined treatment with ursodeoxycholic acid and pioglitazone in a patient with NASH associated with type 2 diabetes and psoriasis. Dig Dis Sci 2003; 48: 2182-2186.
21. Bongartz T, Coras B, Vogt T, et al. Treatment of active psoriatic arthritis with the PPARγ ligand pioglitazone: An open-label pilot study. Rheumatology 2005; 44: 126-129.
22. Reichle A, Bross K, Vogt T, et al. Pioglitazone and rofecoxib combined with angiostatically scheduled trofosfamide in the treatment of far-advanced melanoma and soft tissue sarcoma. Cancer 2004; 101: 2247-2256.
23. Azziz R, Ehrmann D, Legro RS, et al. Troglitazone improves ovulation and hirsutism in the polycystic ovary syndrome: A multicenter, double blind, placebo-controlled trial. J Clin Endocrinol Metab 2001; 86: 1626-1632.
24. Dereli D, Dereli T, Bayraktar F, et al. Endocrine and metabolic effects of rosiglitazone in non-obese women with polycystic ovary disease. Endocr J 2005; 52: 299-308.
25. Yilmaz M, Karakoc A, Toruner FB, et al. The effects of rosiglitazone and metformin on menstrual cyclicity and hirsutism in polycystic ovary syndrome. Gynecol Endocrinol 2005; 21: 154-160.
26. Xin X, Yang S, Kowalski J, et al. Peroxisome proliferators-activated receptor γ ligands are potent inhibitors of angiogenesis in vitro and in vivo. J Biol Chem 1999; 274: 9116-9121.
27. Panigrahy D, Singer S, Shen LQ, et al. PPARγ ligands inhibit primary tumor growth and metastasis by inhibiting angiogenesis. J Clin Invest 2002; 110: 923-932.
28. Vogt T, Hafner C, Bross K, et al. Antiangiogenic therapy with pioglitazone, rofecoxib and metronomic trofosfamide in patients with advanced malignant vascular tumors. Cancer 2003; 98: 2251-2256.
29. Coras B, Hafner C, Reichle A, et al. Antiangiogenic therapy with pioglitazone, rofecoxib, and trofosfamide in a patient with endemic Kaposi sarcoma. Arch Dermatol 2004; 140: 1504-1507.
30. Sutinen J, Hakkinen AM, Westerbacak J, et al. Rosiglitazone in the treatment of HAART-associated lipodystrophy: A randomized double-blind placebo-controlled study. Antivir Ther 2003; 8: 199-208.
31. Bastard JP, Caron M, Vidal H, et al. Association between altered expression of adipogenic factor SREBP1 in lipoatrophic adipose tissue from HIV-1-infected patients and abnormal adipocyte differentiation and insulin resistance. Lancet 2002; 359: 1026-1031.
32. Hadigan C, Yawetz S, Thomas A, et al. Metabolic effects of rosiglitazone in HIV lipodystrophy. A randomized controlled trial. Ann Intern Med 2004; 140: 786-794.
33. Lefebvre AM, Laville M, Vega N, et al. Depot-specific differences in adipose tissue gene expression in lean and obese subject. Diabetes 1998; 47: 98-103.
34. Gelato MC, Mynarcik DC, Quick JL, et al. Improved insulin sensitivity and body fat distribution in HIV-infected patients treated with rosiglitazone: A pilot study. J Acquir Immune Defic Syndr 2002; 31: 163-170.
35. Arioglu E, Duncan-Morin J, Sebring N, et al. Efficacy and safety of troglitazone in the treatment of lipodystrophy syndromes. Ann Intern Med 2000; 133: 263-274.
36. Owen KR, Donohoe M, Ellard S, et al. Response to treatment with rosiglitazone in familial partial lipodystrophy due to a mutation in the LMNA gene. Diabetic Med 2003; 20: 823-827.
37. Ludke A, Heck K, Genschel J, et al. Long-term treatment experience in a subject with Dunnigan-type familial partial lipodystrophy: Efficacy of rosiglitazone. Diabetic Med 2005; 22: 1611-1613.
38. Walker UA, Kirschfink M, Peter HH. Improvement of acquired partial lipodystrophy with rosiglitazone despite ongoing complement activation. Rheumatology 2003; 42: 393-394.
39. Walli R, Michl GM, Muhlbayer D, et al. Effects of troglitazone on insulin sensitivity in HIV-infected patients with protease inhibitor-associated diabetes mellitus. Res Exp Med 2000; 199: 253-262.
40. Sutinen J. Interventions for managing antiretroviral therapy-associated lipoatrophy. Curr Opin Infect Dis 2005; 18: 25-33.
41. Yki-Jarvinen H, Sutinen J, Silveira A, et al. Regulation of plasma PAI-1 concentrations in HAART-associated lipodystrophy during rosiglitazone therapy. Arterioscler Thromb Vasc Biol 2003; 23: 688-694.
42. Carr A, Workman C, Carey D, et al. No effect of rosiglitazone for treatment of HIV-1 lipoatrophy: Randomized, double-blind, placebo-controlled trial. Lancet 2003; 363: 429-438.
43. Calmy A, Hirschel B, Hans D, et al. Glitazones in lipodystrophy syndrome induced by highly active antiretroviral therapy. AIDS 2003; 17: 770-772.
44. Van Wijk J, de Koning EJP, Castro EM, et al. Comparison of rosiglitazone and metformin for treating HIV lipodystrophy: A randomized trial. Ann Intern Med 2005; 143: 337-346.
45. Okura T, Nakamura M, Takata Y, et al. Troglitazone induces apoptosis via the p53 and Gadd45 pathway in vascular smooth muscle cells. Eur J Pharmacol 2000; 407: 227-235.
46. O'Leary R, Ponnambalam S, Wood EJ. Pioglitazone-induced myofibroblast cell death: Implications for cutaneous scarring. Br J Dermatol 2003; 149: 655-680.
47. Bhagavathula N, Nerusu KC, Lal A, et al. Rosiglitazone inhibits proliferation, motility and matrix metalloproteinase production in keratinocytes. J Invest Dermatol 2004; 122: 130-139.